- Home
- MFIN vs FENC Comparison
MFIN vs FENC Comparison
Compare MFIN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- FENC
- Stock Information
- Founded
- MFIN 1995
- FENC 1996
- Country
- MFIN United States
- FENC United States
- Employees
- MFIN N/A
- FENC N/A
- Industry
- MFIN Finance: Consumer Services
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFIN Finance
- FENC Health Care
- Exchange
- MFIN Nasdaq
- FENC Nasdaq
- Market Cap
- MFIN 190.0M
- FENC 156.9M
- IPO Year
- MFIN 1996
- FENC 2001
- Fundamental
- Price
- MFIN $9.42
- FENC $5.74
- Analyst Decision
- MFIN
- FENC Strong Buy
- Analyst Count
- MFIN 0
- FENC 2
- Target Price
- MFIN N/A
- FENC $14.00
- AVG Volume (30 Days)
- MFIN 45.0K
- FENC 68.3K
- Earning Date
- MFIN 02-18-2025
- FENC 11-07-2024
- Dividend Yield
- MFIN 4.67%
- FENC N/A
- EPS Growth
- MFIN N/A
- FENC N/A
- EPS
- MFIN 1.69
- FENC N/A
- Revenue
- MFIN $293,257,000.00
- FENC $49,348,000.00
- Revenue This Year
- MFIN N/A
- FENC $170.43
- Revenue Next Year
- MFIN $11.69
- FENC $6.70
- P/E Ratio
- MFIN $5.51
- FENC N/A
- Revenue Growth
- MFIN 18.48
- FENC 278.09
- 52 Week Low
- MFIN $6.48
- FENC $3.96
- 52 Week High
- MFIN $10.50
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- MFIN 49.77
- FENC 46.75
- Support Level
- MFIN $9.24
- FENC $5.47
- Resistance Level
- MFIN $9.52
- FENC $6.19
- Average True Range (ATR)
- MFIN 0.27
- FENC 0.25
- MACD
- MFIN 0.01
- FENC -0.09
- Stochastic Oscillator
- MFIN 82.93
- FENC 24.77
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. Its operating segments include recreation, home improvement, commercial lending, medallion lending and Corporate and Other Investments. The company generates maximum revenue from the Recreation segment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.